Tempest Therpeutics Inc (TPST) Options

TPST...$1.44s clearing on the 50MA Break...🥳

TPST...$1.50s clearing into the close...🥳

Have a Great Weekend Y'all...🥳

Nice...will be very pleased with 1/2 that target...🥳

Bought a starter today.
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
12:54 PM ET 8/15/24 | Dow Jones

TPST...$1.35...🥳

TPST...$1.44...HOD...🥳

TPST...$1.50...Off the .90 range dip...🥳...was $6 recently...setting up for a Breakout...imo...we shall see...

TPST...1.4995...HOD...Beauty move off the .90 range dip...🥳Was $6 a couple of months ago...🥳

TPST...$1.60 off the $2 plus move from .90 range...🥳

TPST...$2.00 ...Clearing here...🥳

TPST...$1.24...🥳...BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).

"We are thrilled with the positive outcome of our end-of-Phase 2 meeting with the FDA,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest. “Tempest and the FDA are in broad agreement on all major aspects of the proposed pivotal Phase 3 clinical trial for amezalpat in patients with hepatocellular carcinoma in the first line setting. This planned Phase 3 study closely mirrors the randomized Phase 2 study and the strongly favorable hazard ratio for overall survival observed at top-line analysis of the Phase 2, confirmed at the latest survival follow-up, give us confidence in the potential success of the Phase 3.”

Key outcomes of the FDA meeting include:

Agreement on Phase 3 study design, including the standard-of-care control arm and the primary and secondary study endpoints
Agreement on appropriateness of the current amezalpat dose and schedule for the Phase 3 study
Agreement on the Phase 3 statistical plan including a pre-specified early efficacy analysis that the company currently estimates could shorten the time to primary analysis by up to 8 months

TPST...$1.25s clearing here...off the .90 range dip...🥳

TPST...$1.17s clearing here...🥳

TPST...$1.20...added more in this range...🥳

TPST...$1.21s clearing here as volume hits...🥳

TPST...$1.05...Setting up Bullish Harami...Reversal Pattern...🥳

TPST...97...added a few here...🥳

TPST...$1.16...Taking a hit on earnings...adding more down here...🥳

TPST...$1.53s clearing here...🥳

TPST...$1.80...setting up Reversal Candle here...adding...🥳

Yup...nice buy for the CEO...🥳

TPST...$2.14...adding down here...🥳

Form 4

TPST...$2.25s clearing here...🥳

TPST...$2.18...Forming a Bullish Engulfing Candle...🥳

fucking turds

Lol offering upsized right after the news..

in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m.

yup and time to go up even more let's pass 7 and up trmw

UPstink today

TPST under $4

El stinko day today

Any other bio cheapies besides hook

Was that you 3.12 big

OUT AT 3.53:))))

$3.43:))))

FROM 2.92 MY CALL.NOW 3.38:))))

AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.

ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))

This is their reload zone evidently..price going higher

Under 15min remaining for them to fake-volume trade this..lol

Price rising with volume

Wonder which partner Tempest selects for its TPST treatment.

“Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”

20k share trade at $3.42

Grabbed $3.50’s..should find out who they partnered with..soon enough

Grabbed some $3.70’s for next run over $5

Must be todays conference causing rally

Up 13%